-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Only for medical professionals to read and reference from 19:00-20:10, November 23, 2021, "Post-AASLD 2021 Hepatitis B Special" will be broadcast live on the Jizhiyi platform.
We will not see each other~ "For 4 consecutive days, every night at 10: 00- 10:30 in the morning to stay up late to study uninterrupted, more than 20 oral reports on HBV progress, more than 200 HBV research posters.
.
.
This content is too much.
.
.
" This is November 12 During the 15th (Eastern Time), a clinician who "drew dark circles" told us his most intuitive impression of the 72nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2021)
.
I have to say that the annual AASLD academic feast kicked off once again, gathering the clouds, communicating progress, and the vast amount of knowledge
.
As far as the HBV field is concerned, the comprehensive management of viral hepatitis diagnosis and treatment plans is still a hot topic, and the discussion has never stopped! So have you studied the latest research content seriously? Is it a qualified AASLD-HBVer? Come! It’s the time to "take the test".
Let’s first answer the AASLD must ask knowledge list together~ Quick question and answer: How is the answer? Are there some problems that are still tricky? Don't worry, pick one from a hundred, fully prepared, the HBV essence will give you the answer! On November 23, 19:00-20:10 "Post-AASLD 2021 Hepatitis B Special" Let’s see what they say? Scan the QR code below to watch the live broadcast of Professor Ji Dong-Progress in the treatment of chronic hepatitis B.
At present, the situation of viral hepatitis prevention and control in China is still severe
.
According to statistics, there are about 70 million people infected with hepatitis B virus in China, of which 28 million are chronic hepatitis B patients [1]
.
The diagnosis rate and treatment rate of hepatitis B are still low, and we still have a long way to go before the goal of eliminating viral hepatitis
.
As a first-line antiviral drug recommended by domestic and foreign guidelines, the clinical data of propofol tenofovir (TAF) has always been a research hotspot
.
At this year's AASLD, a number of research data on the use of TAF in different populations of chronic hepatitis B were freshly released
.
In newly treated patients with chronic hepatitis B (CHB), the importance of assessing HBsAg levels is again mentioned.
The data show [2] that baseline HBsAg levels are an independent risk that affects the virological response of patients after TAF treatment (48 weeks) Factors
.
In patients treated for hepatitis B, hypoviremia and drug resistance are risk factors that affect the prognosis of patients
.
At the same time, the latest data at the current AASLD meeting [3] indicates that patients with hypoviremia treated with entecavir (ETV), the virological inhibition rate and ALT reversion rate of the conversion to TAF treatment are significantly increased; for multi-drug-resistant hepatitis B after treatment For patients [4], the effectiveness and safety data of 3 years after switching to TAF treatment were announced at this meeting
.
In addition, the treatment of special populations with chronic hepatitis B is also the focus of attention
.
Relevant studies have shown [5] that the patients undergoing liver transplantation from tenofovir disoproxil (TDF) to TAF treatment can effectively prevent disease recurrence and improve the safety of bone and kidney
.
Professor Qing Xie——Problems of concern in long-term antiviral treatment At present, relevant guidelines on CHB treatment at home and abroad point out that the goal of CHB antiviral treatment is to inhibit HBV replication for a long time to the greatest extent, prevent disease progression, delay and reduce liver function Failure, decompensation of liver cirrhosis, hepatocellular carcinoma (HCC) and other complications occur, thereby improving the quality of life of patients and prolonging survival time [6-9]
.
The results of a population-based study at the current AASLD conference [10] showed that severe hepatitis outbreaks are not uncommon and may even be fatal in patients with CHB after oral antiviral therapy is discontinued; and long-term antiviral therapy can reduce the risk of HCC.
.
In the process of long-term antiviral treatment for CHB patients, drug safety is one of the focuses that we have been paying attention to
.
The results of a number of real-world studies published at the AASLD conference showed that [11-13] that the kidney safety after TAF treatment or conversion to TAF treatment in CHB patients is good; at the same time, TDF is used in CHB patients at risk of bone disease.
After TAF treatment, bone density has improved [13]
.
In addition, patients receiving TAF and TDF treatment have similar risks of developing ASCVD cardiovascular disease in the future [14]
.
Although the event has ended, the excitement continues
.
The latest and hottest hepatitis B knowledge list is in the "Post-AASLD 2021 Hepatitis B Special"! At seven o'clock in the evening on November 23, we will see you or leave! References: 1.
Liu J, Liang W, Jing W, et al.
Countdown to 2030: Eliminating hepatitis B disease, China[J].
Bull World Health Organ, 2019, 97(3): 230-238.
2.
Peng Chen, et al.
Effectiveness of and predictors associated with virologic response to tenofovir alafenamide (TAF) in nucleoside (tide) analogue (NA) treatment naïve patients with chronic hepatitis B (CHB) in China.
AASLD 2021.
Poster abstract 782.
3.
Dong Ji, et al.
Tenofovir alafenamide for the treatment of chronic hepatitis B patients with low-level viremia: a prospective real-world study.
AASLD 2021.
Poster abstract 813.
4.
Jonggi Choi, et al.
Tenofovir alafenamide for multiple drug-resistant chronic hepatitis B: a 3-Year clinical trial.
AASLD 2021.
Poster abstract 812.
5.
Edward J Gane, et al. .
If you are not a medical and health professional, please do not participate or spread it
.
-End-This article is only used to provide scientific information to medical professionals and does not represent the platform's position
.
We will not see each other~ "For 4 consecutive days, every night at 10: 00- 10:30 in the morning to stay up late to study uninterrupted, more than 20 oral reports on HBV progress, more than 200 HBV research posters.
.
.
This content is too much.
.
.
" This is November 12 During the 15th (Eastern Time), a clinician who "drew dark circles" told us his most intuitive impression of the 72nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2021)
.
I have to say that the annual AASLD academic feast kicked off once again, gathering the clouds, communicating progress, and the vast amount of knowledge
.
As far as the HBV field is concerned, the comprehensive management of viral hepatitis diagnosis and treatment plans is still a hot topic, and the discussion has never stopped! So have you studied the latest research content seriously? Is it a qualified AASLD-HBVer? Come! It’s the time to "take the test".
Let’s first answer the AASLD must ask knowledge list together~ Quick question and answer: How is the answer? Are there some problems that are still tricky? Don't worry, pick one from a hundred, fully prepared, the HBV essence will give you the answer! On November 23, 19:00-20:10 "Post-AASLD 2021 Hepatitis B Special" Let’s see what they say? Scan the QR code below to watch the live broadcast of Professor Ji Dong-Progress in the treatment of chronic hepatitis B.
At present, the situation of viral hepatitis prevention and control in China is still severe
.
According to statistics, there are about 70 million people infected with hepatitis B virus in China, of which 28 million are chronic hepatitis B patients [1]
.
The diagnosis rate and treatment rate of hepatitis B are still low, and we still have a long way to go before the goal of eliminating viral hepatitis
.
As a first-line antiviral drug recommended by domestic and foreign guidelines, the clinical data of propofol tenofovir (TAF) has always been a research hotspot
.
At this year's AASLD, a number of research data on the use of TAF in different populations of chronic hepatitis B were freshly released
.
In newly treated patients with chronic hepatitis B (CHB), the importance of assessing HBsAg levels is again mentioned.
The data show [2] that baseline HBsAg levels are an independent risk that affects the virological response of patients after TAF treatment (48 weeks) Factors
.
In patients treated for hepatitis B, hypoviremia and drug resistance are risk factors that affect the prognosis of patients
.
At the same time, the latest data at the current AASLD meeting [3] indicates that patients with hypoviremia treated with entecavir (ETV), the virological inhibition rate and ALT reversion rate of the conversion to TAF treatment are significantly increased; for multi-drug-resistant hepatitis B after treatment For patients [4], the effectiveness and safety data of 3 years after switching to TAF treatment were announced at this meeting
.
In addition, the treatment of special populations with chronic hepatitis B is also the focus of attention
.
Relevant studies have shown [5] that the patients undergoing liver transplantation from tenofovir disoproxil (TDF) to TAF treatment can effectively prevent disease recurrence and improve the safety of bone and kidney
.
Professor Qing Xie——Problems of concern in long-term antiviral treatment At present, relevant guidelines on CHB treatment at home and abroad point out that the goal of CHB antiviral treatment is to inhibit HBV replication for a long time to the greatest extent, prevent disease progression, delay and reduce liver function Failure, decompensation of liver cirrhosis, hepatocellular carcinoma (HCC) and other complications occur, thereby improving the quality of life of patients and prolonging survival time [6-9]
.
The results of a population-based study at the current AASLD conference [10] showed that severe hepatitis outbreaks are not uncommon and may even be fatal in patients with CHB after oral antiviral therapy is discontinued; and long-term antiviral therapy can reduce the risk of HCC.
.
In the process of long-term antiviral treatment for CHB patients, drug safety is one of the focuses that we have been paying attention to
.
The results of a number of real-world studies published at the AASLD conference showed that [11-13] that the kidney safety after TAF treatment or conversion to TAF treatment in CHB patients is good; at the same time, TDF is used in CHB patients at risk of bone disease.
After TAF treatment, bone density has improved [13]
.
In addition, patients receiving TAF and TDF treatment have similar risks of developing ASCVD cardiovascular disease in the future [14]
.
Although the event has ended, the excitement continues
.
The latest and hottest hepatitis B knowledge list is in the "Post-AASLD 2021 Hepatitis B Special"! At seven o'clock in the evening on November 23, we will see you or leave! References: 1.
Liu J, Liang W, Jing W, et al.
Countdown to 2030: Eliminating hepatitis B disease, China[J].
Bull World Health Organ, 2019, 97(3): 230-238.
2.
Peng Chen, et al.
Effectiveness of and predictors associated with virologic response to tenofovir alafenamide (TAF) in nucleoside (tide) analogue (NA) treatment naïve patients with chronic hepatitis B (CHB) in China.
AASLD 2021.
Poster abstract 782.
3.
Dong Ji, et al.
Tenofovir alafenamide for the treatment of chronic hepatitis B patients with low-level viremia: a prospective real-world study.
AASLD 2021.
Poster abstract 813.
4.
Jonggi Choi, et al.
Tenofovir alafenamide for multiple drug-resistant chronic hepatitis B: a 3-Year clinical trial.
AASLD 2021.
Poster abstract 812.
5.
Edward J Gane, et al. .
If you are not a medical and health professional, please do not participate or spread it
.
-End-This article is only used to provide scientific information to medical professionals and does not represent the platform's position
.
